Emily Miyoshi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Emily Miyoshi has a total of 118 co-authors. Here are the top co-authors by number of shared publications:
- Vivek Swarup
Department of Neurobiology and Behavior, University of California Irvine
7 shared publications - Samuel Morabito
Centro Nacional de Análisis Genómico (CNAG), Barcelona, Spain
6 shared publications - Elizabeth Head
Department of Pathology and Laboratory Medicine, University of California, Irvine, Irvine, CA, United States
4 shared publications Neethu Michael
Department of Neurobiology and Behavior, University of California, Irvine, Irvine, USA
4 shared publicationsSudeshna Das
Department of Neurobiology and Behavior, Charlie Dunlop School of Biological Sciences, University of California, Irvine, Irvine, CA 92697, USA
4 shared publicationsTina Bilousova
UCLA School of Nursing, UCLA School of Medicine, Los Angeles, CA, USA
3 shared publications
Latest Publications
- Open Access
- 14 November 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (46) , eads7973
Single-nucleus multi-omics identifies shared and distinct pathways in Pick’s and Alzheimer’s disease
The study of transcriptomic and epigenomic variations in neurodegenerative diseases, particularly tauopathies like Pick’s disease (PiD) and Alzheimer’s disease (AD), offers insights into their underlying regulatory mechanisms. Here, we identified critical regulatory changes driving disease progression, revealing potential therapeutic targets. Our comparative analyses uncovered disease-enriched noncoding regions and genome-wide transcription factor (TF) binding differences, linking them to target genes. Notably, we identified a distal human-gained enhancer (HGE) associated with E3 ubiquitin ligase (UBE3A), highlighting disease-specific regulatory alterations. Additionally, fine mapping of AD risk genes uncovered loci enriched in microglial enhancers and accessible in other cell types. Shared and distinct TF binding patterns were observed in neurons and glial cells across PiD and AD. We validated our findings using CRISPR to excise a predicted enhancer region in UBE3A and developed an interactive database, scROAD, to visualize predicted single-cell TF occupancy and regulatory networks.
- 14 November 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (46) , eads7973
Open AccessSingle-nucleus multi-omics identifies shared and distinct pathways in Pick’s and Alzheimer’s disease
The study of transcriptomic and epigenomic variations in neurodegenerative diseases, particularly tauopathies like Pick’s disease (PiD) and Alzheimer’s disease (AD), offers insights into their underlying regulatory mechanisms. Here, we identified critical regulatory changes driving disease progression, revealing potential therapeutic targets. Our comparative analyses uncovered disease-enriched noncoding regions and genome-wide transcription factor (TF) binding differences, linking them to target genes. Notably, we identified a distal human-gained enhancer (HGE) associated with E3 ubiquitin ligase (UBE3A), highlighting disease-specific regulatory alterations. Additionally, fine mapping of AD risk genes uncovered loci enriched in microglial enhancers and accessible in other cell types. Shared and distinct TF binding patterns were observed in neurons and glial cells across PiD and AD. We validated our findings using CRISPR to excise a predicted enhancer region in UBE3A and developed an interactive database, scROAD, to visualize predicted single-cell TF occupancy and regulatory networks.
- Open Access
- 8 July 2025
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 53 (13)
Splice-modulating antisense oligonucleotides targeting a pathogenic intronic variant in adult polyglucosan body disease correct mis-splicing and restore enzyme activity in patient cells
Adult polyglucosan body disease (APBD) is a rare, adult-onset neurodegenerative disorder caused by loss-of-function variants in the glycogen branching enzyme (GBE1) gene, essential for glycogen biosynthesis. The second most common pathogenic mutation in APBD (c.2053-3358_2053-3350delinsTGTTTTTTACATGACAGGT) is a deep intronic deletion insertion (indel) variant creating an ectopic splice acceptor site, resulting in a mutant transcript with a pseudoexon encoding an unstable truncated protein. Such mutations can be effectively targeted with splice-modulating antisense oligonucleotides (ASOs) to restore normal splicing. Here, we characterized the indel in-depth using long-read sequencing techniques and discovered several new features of the mutant transcript. The indel sequence varies from the previously identified sequence by a nucleotide, and the usage of the ectopic splice site results in two mutant isoforms, both of which are targets of cellular nonsense-mediated decay. High-throughput screening in patient-derived fibroblasts identified multiple lead candidates that effectively blocked the ectopic splice site and increased the canonical GBE1 transcript and protein. Functional analysis confirmed that treatment with the lead ASOs significantly improved GBE1 enzyme activity in patient cells, validating their therapeutic potential. Taken together, our data demonstrate the successful discovery of ASOs that correct mis-splicing, thus offering a promising treatment for a subset of APBD patients.
- 8 July 2025
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 53 (13)
Open AccessSplice-modulating antisense oligonucleotides targeting a pathogenic intronic variant in adult polyglucosan body disease correct mis-splicing and restore enzyme activity in patient cells
Adult polyglucosan body disease (APBD) is a rare, adult-onset neurodegenerative disorder caused by loss-of-function variants in the glycogen branching enzyme (GBE1) gene, essential for glycogen biosynthesis. The second most common pathogenic mutation in APBD (c.2053-3358_2053-3350delinsTGTTTTTTACATGACAGGT) is a deep intronic deletion insertion (indel) variant creating an ectopic splice acceptor site, resulting in a mutant transcript with a pseudoexon encoding an unstable truncated protein. Such mutations can be effectively targeted with splice-modulating antisense oligonucleotides (ASOs) to restore normal splicing. Here, we characterized the indel in-depth using long-read sequencing techniques and discovered several new features of the mutant transcript. The indel sequence varies from the previously identified sequence by a nucleotide, and the usage of the ectopic splice site results in two mutant isoforms, both of which are targets of cellular nonsense-mediated decay. High-throughput screening in patient-derived fibroblasts identified multiple lead candidates that effectively blocked the ectopic splice site and increased the canonical GBE1 transcript and protein. Functional analysis confirmed that treatment with the lead ASOs significantly improved GBE1 enzyme activity in patient cells, validating their therapeutic potential. Taken together, our data demonstrate the successful discovery of ASOs that correct mis-splicing, thus offering a promising treatment for a subset of APBD patients.
- Top Cited PapersOpen Access
- 22 November 2024
- Published by Springer Nature in Nature Genetics
- Vol. 56 (12) , 2704-2717
Spatial and single-nucleus transcriptomic analysis of genetic and sporadic forms of Alzheimer’s disease
The pathogenesis of Alzheimer’s disease (AD) depends on environmental and heritable factors, with its molecular etiology still unclear. Here we present a spatial transcriptomic (ST) and single-nucleus transcriptomic survey of late-onset sporadic AD and AD in Down syndrome (DSAD). Studying DSAD provides an opportunity to enhance our understanding of the AD transcriptome, potentially bridging the gap between genetic mouse models and sporadic AD. We identified transcriptomic changes that may underlie cortical layer-preferential pathology accumulation. Spatial co-expression network analyses revealed transient and regionally restricted disease processes, including a glial inflammatory program dysregulated in upper cortical layers and implicated in AD genetic risk and amyloid-associated processes. Cell–cell communication analysis further contextualized this gene program in dysregulated signaling networks. Finally, we generated ST data from an amyloid AD mouse model to identify cross-species amyloid-proximal transcriptomic changes with conformational context.
- 22 November 2024
- Published by Springer Nature in Nature Genetics
- Vol. 56 (12) , 2704-2717
Top Cited PapersOpen AccessSpatial and single-nucleus transcriptomic analysis of genetic and sporadic forms of Alzheimer’s disease
The pathogenesis of Alzheimer’s disease (AD) depends on environmental and heritable factors, with its molecular etiology still unclear. Here we present a spatial transcriptomic (ST) and single-nucleus transcriptomic survey of late-onset sporadic AD and AD in Down syndrome (DSAD). Studying DSAD provides an opportunity to enhance our understanding of the AD transcriptome, potentially bridging the gap between genetic mouse models and sporadic AD. We identified transcriptomic changes that may underlie cortical layer-preferential pathology accumulation. Spatial co-expression network analyses revealed transient and regionally restricted disease processes, including a glial inflammatory program dysregulated in upper cortical layers and implicated in AD genetic risk and amyloid-associated processes. Cell–cell communication analysis further contextualized this gene program in dysregulated signaling networks. Finally, we generated ST data from an amyloid AD mouse model to identify cross-species amyloid-proximal transcriptomic changes with conformational context.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S12)
Integrated spatial and single‐cell transcriptomic analysis of genetic and sporadic forms of Alzheimer’s disease
Background: The pathogenesis of Alzheimer’s disease (AD) varies greatly depending on environmental and heritable factors. Neuropathological scores aid in the understanding of disease severity in postmortem tissue, but fail to provide insights into disease onset and progression. Conversely, mouse models of AD like 5XFAD offer predictable timelines of amyloid accumulation due to specific human AD risk signals, but have limitations due to species differences. Studying AD in Down Syndrome (AD in DS) patients provides an opportunity to study the transcriptomics of AD progression due to overexpression of APP, which results in a more predictable disease time course compared to the more stochastic disease progression in the general population.Method: We present a rigorous transcriptomic analysis of AD using single‐nucleus RNA‐seq (snRNA‐seq) and spatial transcriptomics (ST) in cortical samples from donors with early‐stage AD, late‐stage AD, AD in DS, and cognitively normal controls. We performed ST (10X Genomics Visium) in these groups, and additionally performed snRNA‐seq (Parse Biosciences) in tissue from AD in DS donors and controls. Finally, we profiled 5XFAD and wild type mice at four time points (4, 6, 8, and 12 months) using ST to facilitate cross‐species comparisons. We applied state‐of‐the‐art bioinformatic and statistical approaches to integrate these datasets with published AD snRNA‐seq data and to perform systematic analyses of gene expression and gene networks in these groups.Result: We found shared and distinct differentially expressed genes (DEGs) between AD and AD in DS in the ST and snRNA‐seq datasets, with greater concordance in neuronal cell types compared to glia. Cell‐cell communication network analysis of integrated snRNA‐seq and ST data revealed vast network remodeling in disease, highlighting an increase in WNT and ANGPTL signaling and a decrease in CD99 signaling among other disrupted pathways. Using geospatial statistical analysis, we identified amyloid plaque proximal DEGs in human and mouse ST data, which were largely species‐specific with little overlap.Conclusion: The primary data generated here will be a valuable resource for the AD community, and our study provides new insights into the transcriptomics of AD and amyloid pathology by performing a holistic analysis considering sporadic and genetic forms of AD.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S12)
Open AccessIntegrated spatial and single‐cell transcriptomic analysis of genetic and sporadic forms of Alzheimer’s disease
Background: The pathogenesis of Alzheimer’s disease (AD) varies greatly depending on environmental and heritable factors. Neuropathological scores aid in the understanding of disease severity in postmortem tissue, but fail to provide insights into disease onset and progression. Conversely, mouse models of AD like 5XFAD offer predictable timelines of amyloid accumulation due to specific human AD risk signals, but have limitations due to species differences. Studying AD in Down Syndrome (AD in DS) patients provides an opportunity to study the transcriptomics of AD progression due to overexpression of APP, which results in a more predictable disease time course compared to the more stochastic disease progression in the general population.Method: We present a rigorous transcriptomic analysis of AD using single‐nucleus RNA‐seq (snRNA‐seq) and spatial transcriptomics (ST) in cortical samples from donors with early‐stage AD, late‐stage AD, AD in DS, and cognitively normal controls. We performed ST (10X Genomics Visium) in these groups, and additionally performed snRNA‐seq (Parse Biosciences) in tissue from AD in DS donors and controls. Finally, we profiled 5XFAD and wild type mice at four time points (4, 6, 8, and 12 months) using ST to facilitate cross‐species comparisons. We applied state‐of‐the‐art bioinformatic and statistical approaches to integrate these datasets with published AD snRNA‐seq data and to perform systematic analyses of gene expression and gene networks in these groups.Result: We found shared and distinct differentially expressed genes (DEGs) between AD and AD in DS in the ST and snRNA‐seq datasets, with greater concordance in neuronal cell types compared to glia. Cell‐cell communication network analysis of integrated snRNA‐seq and ST data revealed vast network remodeling in disease, highlighting an increase in WNT and ANGPTL signaling and a decrease in CD99 signaling among other disrupted pathways. Using geospatial statistical analysis, we identified amyloid plaque proximal DEGs in human and mouse ST data, which were largely species‐specific with little overlap.Conclusion: The primary data generated here will be a valuable resource for the AD community, and our study provides new insights into the transcriptomics of AD and amyloid pathology by performing a holistic analysis considering sporadic and genetic forms of AD.
- Open Access
- 5 November 2023
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 15, S931
EXPLORING PLAQUE-ASSOCIATED GENE EXPRESSION IN ALZHEIMER'S DISEASE THROUGH SPATIAL TRANSCRIPTOMICS IN HUMAN AND MOUSE MODELS
- 5 November 2023
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 15, S931
Open AccessEXPLORING PLAQUE-ASSOCIATED GENE EXPRESSION IN ALZHEIMER'S DISEASE THROUGH SPATIAL TRANSCRIPTOMICS IN HUMAN AND MOUSE MODELS
- Open Access
- 21 December 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-23
Huntington disease oligodendrocyte maturation deficits revealed by single-nucleus RNAseq are rescued by thiamine-biotin supplementation
The complexity of affected brain regions and cell types is a challenge for Huntington’s disease (HD) treatment. Here we use single nucleus RNA sequencing to investigate molecular pathology in the cortex and striatum from R6/2 mice and human HD post-mortem tissue. We identify cell type-specific and -agnostic signatures suggesting oligodendrocytes (OLs) and oligodendrocyte precursors (OPCs) are arrested in intermediate maturation states. OL-lineage regulatorsOLIG1andOLIG2are negatively correlated with CAG length in human OPCs, and ATACseq analysis of HD mouse NeuN-negative cells shows decreased accessibility regulated by OL maturation genes. The data implicates glucose and lipid metabolism in abnormal cell maturation and identifyPRKCEand Thiamine Pyrophosphokinase 1 (TPK1) as central genes. Thiamine/biotin treatment of R6/1 HD mice to compensate forTPK1dysregulation restores OL maturation and rescues neuronal pathology. Our insights into HD OL pathology spans multiple brain regions and link OL maturation deficits to abnormal thiamine metabolism.
- 21 December 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-23
Open AccessHuntington disease oligodendrocyte maturation deficits revealed by single-nucleus RNAseq are rescued by thiamine-biotin supplementation
The complexity of affected brain regions and cell types is a challenge for Huntington’s disease (HD) treatment. Here we use single nucleus RNA sequencing to investigate molecular pathology in the cortex and striatum from R6/2 mice and human HD post-mortem tissue. We identify cell type-specific and -agnostic signatures suggesting oligodendrocytes (OLs) and oligodendrocyte precursors (OPCs) are arrested in intermediate maturation states. OL-lineage regulatorsOLIG1andOLIG2are negatively correlated with CAG length in human OPCs, and ATACseq analysis of HD mouse NeuN-negative cells shows decreased accessibility regulated by OL maturation genes. The data implicates glucose and lipid metabolism in abnormal cell maturation and identifyPRKCEand Thiamine Pyrophosphokinase 1 (TPK1) as central genes. Thiamine/biotin treatment of R6/1 HD mice to compensate forTPK1dysregulation restores OL maturation and rescues neuronal pathology. Our insights into HD OL pathology spans multiple brain regions and link OL maturation deficits to abnormal thiamine metabolism.
- Open Access
- 14 June 2022
- Published by Elsevier in Cell Reports
- Vol. 39 (11) , 110961
Absence of microglia promotes diverse pathologies and early lethality in Alzheimer’s disease mice
- 14 June 2022
- Published by Elsevier in Cell Reports
- Vol. 39 (11) , 110961
Open AccessAbsence of microglia promotes diverse pathologies and early lethality in Alzheimer’s disease mice
- Open Access
- 30 August 2021
- Published by Elsevier in Laboratory Investigation
- Vol. 101 (12) , 1605-1617
Exosomal tau with seeding activity is released from Alzheimer's disease synapses, and seeding potential is associated with amyloid beta
- 30 August 2021
- Published by Elsevier in Laboratory Investigation
- Vol. 101 (12) , 1605-1617
Open AccessExosomal tau with seeding activity is released from Alzheimer's disease synapses, and seeding potential is associated with amyloid beta
- Top Cited Papers
- 8 July 2021
- Published by Springer Nature in Nature Genetics
- Vol. 53 (8) , 1143-1155
Single-nucleus chromatin accessibility and transcriptomic characterization of Alzheimer’s disease
The gene-regulatory landscape of the brain is highly dynamic in health and disease, coordinating a menagerie of biological processes across distinct cell types. Here, we present a multi-omic single-nucleus study of 191,890 nuclei in late-stage Alzheimer’s disease (AD), accessible through our web portal, profiling chromatin accessibility and gene expression in the same biological samples and uncovering vast cellular heterogeneity. We identified cell-type-specific, disease-associated candidate cis-regulatory elements and their candidate target genes, including an oligodendrocyte-associated regulatory module containing links to APOE and CLU. We describe cis-regulatory relationships in specific cell types at a subset of AD risk loci defined by genome-wide association studies, demonstrating the utility of this multi-omic single-nucleus approach. Trajectory analysis of glial populations identified disease-relevant transcription factors, such as SREBF1, and their regulatory targets. Finally, we introduce single-nucleus consensus weighted gene coexpression analysis, a coexpression network analysis strategy robust to sparse single-cell data, and perform a systems-level analysis of the AD transcriptome.
- 8 July 2021
- Published by Springer Nature in Nature Genetics
- Vol. 53 (8) , 1143-1155
Top Cited PapersSingle-nucleus chromatin accessibility and transcriptomic characterization of Alzheimer’s disease
The gene-regulatory landscape of the brain is highly dynamic in health and disease, coordinating a menagerie of biological processes across distinct cell types. Here, we present a multi-omic single-nucleus study of 191,890 nuclei in late-stage Alzheimer’s disease (AD), accessible through our web portal, profiling chromatin accessibility and gene expression in the same biological samples and uncovering vast cellular heterogeneity. We identified cell-type-specific, disease-associated candidate cis-regulatory elements and their candidate target genes, including an oligodendrocyte-associated regulatory module containing links to APOE and CLU. We describe cis-regulatory relationships in specific cell types at a subset of AD risk loci defined by genome-wide association studies, demonstrating the utility of this multi-omic single-nucleus approach. Trajectory analysis of glial populations identified disease-relevant transcription factors, such as SREBF1, and their regulatory targets. Finally, we introduce single-nucleus consensus weighted gene coexpression analysis, a coexpression network analysis strategy robust to sparse single-cell data, and perform a systems-level analysis of the AD transcriptome.
- 1 August 2019
- Published by Elsevier in The American Journal of Pathology
- Vol. 189 (8) , 1621-1636
Apolipoprotein E/Amyloid-β Complex Accumulates in Alzheimer Disease Cortical Synapses via Apolipoprotein E Receptors and Is Enhanced by APOE4
- 1 August 2019
- Published by Elsevier in The American Journal of Pathology
- Vol. 189 (8) , 1621-1636
Apolipoprotein E/Amyloid-β Complex Accumulates in Alzheimer Disease Cortical Synapses via Apolipoprotein E Receptors and Is Enhanced by APOE4